Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 25;35(8):165.
doi: 10.1007/s11095-018-2437-y.

Preclinical Development of Cell-Based Products: A European Regulatory Science Perspective

Free PMC article

Preclinical Development of Cell-Based Products: A European Regulatory Science Perspective

James W McBlane et al. Pharm Res. .
Free PMC article

Erratum in


Purpose: This article describes preclinical development of cell-based medicinal products for European markets and discusses European regulatory mechanisms open to developers to aid successful product development. Cell-based medicinal products are diverse, including cells that are autologous or allogeneic, have been genetically modified, or not, or expanded ex vivo, and applied systemically or to an anatomical site different to that of their origin; comments applicable to one product may not be applicable to others, so bespoke development is needed, for all elements - quality, preclinical and clinical.

Methods: After establishing how the product is produced, proof of potential for therapeutic efficacy, and then safety, of the product need to be determined. This includes understanding biodistribution, persistence and toxicity, including potential for malignant transformation. These elements need to be considered in the context of the intended clinical development.

Results: This article describes regulatory mechanisms available to developers to support product development that aim to resolve scientific issues prior to marketing authorization application, to enable patients to have faster access to the product than would otherwise be the case.

Conclusions: Developers are encouraged to be aware of both the scientific issues and regulatory mechanisms to ensure patients can be supplied with these products.

Keywords: biodistribution; cell therapy; regulatory science; toxicity; tumorigenicity.

Similar articles

See all similar articles

Cited by 2 articles


    1. McBlane JW. Preclinical safety testing for cell-based products using animals. Biologicals. 2015;43(5):425–428. doi: 10.1016/j.biologicals.2015.05.002. - DOI - PubMed
    1. Aiuti A, Roncarolo MG, Naldini L. Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med. 2017;9:737–740. doi: 10.15252/emmm.201707573. - DOI - PMC - PubMed
    1. McBlane JW. Regulatory landscape for cell therapy – EU view. Biologicals. 2015;43(5):433–436. doi: 10.1016/j.biologicals.2015.04.004. - DOI - PubMed
    1. Yano K, Watanabe N, Tsuyuki K, Ikawa T, Kasanuki H, Yamato M. Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan. Regen Ther. 2015;1:45–56. doi: 10.1016/j.reth.2014.10.001. - DOI
    1. Vestergaard HT, D'Apote L, Schneider CK, Herberts C. The evolution of nonclinical regulatory science: advanced therapy medicinal products as a paradigm. Mol Ther. 2013;21(9):1644–1648. doi: 10.1038/mt.2013.175. - DOI - PubMed

LinkOut - more resources